海正药业子公司获得新兽药注册证书

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval for its new veterinary drug, Methylprednisolone Tablets (for dogs), marking a significant step in its strategic expansion in the veterinary medicine sector [1] Group 1: Company Developments - The company's subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has been granted a new veterinary drug registration certificate by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The approval of Methylprednisolone Tablets (for dogs) as a Class 5 new veterinary drug indicates compliance with relevant regulations, enhancing the company's competitive position in the veterinary market [1] Group 2: Industry Impact - The approval of this new veterinary product is expected to facilitate the company's strategic layout in the veterinary medicine sector, potentially leading to increased market share and competitiveness [1]